Company Overview of Moffitt Cancer Center
Moffitt Cancer Center is based in the United States.
Key Executives for Moffitt Cancer Center
Chief Nursing Officer and Vice President
Chief Health Information Officer and Vice President
Compensation as of Fiscal Year 2014.
Moffitt Cancer Center Key Developments
Rosetta Genomics Ltd. and Moffitt Cancer Center Enter into Strategic Alliance to Develop Microrna-Based Cancer Diagnostics
Sep 2 14
Rosetta Genomics Ltd. announced that the company has entered into a strategic alliance with Moffitt Cancer Center to discover, develop and commercialize a variety of microRNA-based cancer diagnostics. The three-year alliance brings together the resources and talents of Moffitt with those of Rosetta Genomics to stimulate new projects and collaborations for the development of diagnostics in areas of unmet medical need. Rosetta will provide funding for Moffitt investigator-initiated projects that align with Rosetta's strategic priorities. Rosetta has a proprietary discovery microarray platform with over 2,500 human microRNAs, along with a proprietary RT-PCR platform. Additionally, Rosetta has bioinformatics and microRNA wet lab expertise, with approximately 50 peer-reviewed publications across multiple cancers and other disease states and on many tissue types and body fluids. This strategic alliance will leverage Rosetta's capabilities and expertise.
Chris Sullivan Joins Moffitt Cancer Center Board of Advisors
Aug 5 14
Moffitt Cancer Center announced the appointment of Chris Sullivan to its national Board of Advisors. Sullivan founded Outback Steakhouse in 1988 with Bob Basham, Tim Gannon, and Trudy Cooper and served as former Chairman and CEO of Outback Steakhouse (OSI).
Rosetta and Moffitt Enter into Agreement to Develop Thyroid Neoplasia Assay
Jun 27 14
Rosetta Genomics Ltd. and Moffitt Cancer Center have entered into an agreement for the development and commercialization of Rosetta's thyroid neoplasia assay. Under the agreement, Rosetta will work with Marino Leon, associate member of the Department of Anatomic Pathology at Moffitt. A fine needle aspiration (FNA), a non-surgical procedure used to obtain tissue for analysis by a pathologist, is the standard technique for detecting cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries